Drug Search Results
Using advanced filters...
Advanced Search [+]

SP203

Alternative Names: sp203
Clinical Status: Inactive
Latest Update: 2018-07-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: MGLUR Modulator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Institute of Mental Health (NIMH)
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Alzheimer Disease|Blood Protein Disorders|Schizophrenia|Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

07-M-0082

P1

Completed

Alzheimer Disease|Blood Protein Disorders|Schizophrenia|Parkinson's Disease

None

2019-03-21

Treatments

Recent News Events

Date

Type

Title